Loading...
Loading...
In a report published Monday, Credit Suisse analyst Ravi Mehrotra downgraded the rating on
Sucampo Pharmaceuticals, Inc.SCMP from Neutral to Underperform, but raised the price target from $10.00 to $13.00.
In the report, Credit Suisse noted, "We are increasing our TP to $13 (from $10) and downgrading SCMP to underperform. We remain concerned about the longer term competitive threats to SCMP's base business from IRWD's Linzess, which enjoys a superior clinical profile and efficacy. Additionally, while we are sympathetic to its pipeline efforts, we do not believe that it has the potential to achieve a paradigm upward shift in SCMP's outlook."
Sucampo Pharmaceuticals closed on Friday at $15.38.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in